Humacyte enters $60M at-the-market equity offering with TD Cowen

Humacyte, Inc.

Up to $60M in common stock may be sold from time to time through TD Securities (USA) LLC as agent.
TD Cowen will receive a commission of up to 3.0% of gross proceeds.
Net proceeds to fund commercialization of Symvess in vascular trauma, pipeline, and working capital.
Company is not obligated to sell any shares; ATM allows sales at prevailing market prices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.